Zydus Life Arm Inks Deal with MSN for Tablets to Treat Advanced Kidney Cancer

Zydus Life's wholly owned subsidiary Zydus Lifesciences Global FZE on Friday entered into a significant licensing and supply agreement with MSN Laboratories for the Cabozantinib tablets to treat advanced kidney cancer, in the US.. 

 

Key Takeaways from the Agreement:

 

  • Zydus Life arm inked a licensing and supply agreement with MSN Laboratories for the US market for the Cabozantinib tablets to treat advanced kidney cancer.
  • MSN Lab will help manufacture and supply the generic version of the CABOMETYX drug.
  • Zydus Lifesciences Global FZE will distribute and sell the product in the US market.
  • The total addressable opportunity of cabozantinib tablets in the US is approximately $1,464 million.

 

Under the agreement, MSN Laboratories will manufacture and supply the generic version of the CABOMETYX drug while Zydus Lifesciences Global FZE will market, distribute and sell the product in the US market.

 

According to Zydus MD, Sharvil Patel, Cabozantinib is an important treatment option for many cancer patients and the company is pleased to work with MSN to bring the generic version of CABOMETYX to the US market.

 

Working with Zydus will enable the successful commercialisation of the tablet while advancing MSN's mission of enabling access to high-quality, affordable medicines, MSN Reddy, founder, chairman and MD of MSN Group said.

 

As per the IQVIA MAT 20254 data, the total addressable opportunity of cabozantinib tablets in the US is approximately $1,464 million.

 

About Zydus Lifesciences Limited:

 

Zydus Lifesciences Limited, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. Zydus has domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions,  from formulations to active pharmaceutical ingredients and animal healthcare products to wellness products.

 

Read More About Zydus Lifesciences Limited Share Price Here!

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

9 mins read . 11 Oct 2024

Public Sector Undertakings in India

  • 0 people read
blog-logo

Share Market

blog-logo

7 mins read . 11 Oct 2024

How Did Rakesh Jhunjhunwala Become a Billionaire?

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions